Church of PeptidesSearch
Portrait of CagrilintidePortrait of Semaglutide
The Choirs · FDA application submitted

CagriSema

The Satiety Duet

A fixed-dose investigational combination of cagrilintide and semaglutide

CagriSema combines cagrilintide, an amylin receptor agonist, with semaglutide, a GLP-1 receptor agonist, in a defined investigational product. It has combination trial evidence, unlike informal stacks.

Evidence ladder: Controlled human evidenceControlled phase 3 human evidenceCombination record
ClassificationThe Choirs
Evidence summaryControlled phase 3 human evidence
OriginNovo Nordisk · Denmark · phase 3 program launched in the 2020s
Book of the Canon · Comic scripture

The laboratory legend

Cagrilintide brought the amylin score. Semaglutide brought the GLP-1 rhythm. Epistide called it a duet; Doctide called it a phase 3 program with a pending regulatory ending.

This bold passage is invented comedy, not scientific or historical fact.
Documented identity

What is actually in the name

Novo Nordisk developed CagriSema as a fixed-dose combination of the long-acting amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide. REDEFINE 1 was published in 2025. The company states that it submitted CagriSema for U.S. weight-management review in December 2025.

Novo Nordisk · Denmark · phase 3 program launched in the 2020s
Component bookCagrilintide →Component bookSemaglutide →
Scientific record

Evidence for the combination

What is established—or merely proposed

  • REDEFINE 1 was a randomized, double-blind, phase 3 trial in adults with overweight or obesity without diabetes.
  • The published trial found greater body-weight reduction with the combination than with placebo.
  • This is evidence for a defined investigational combination, not evidence for improvised mixtures sold under the same name.

Side effects, risks and limits

  • Gastrointestinal adverse events were common in REDEFINE 1 and were reported more often with the combination than with placebo.
  • Long-term safety, cardiovascular outcomes and the final regulatory label remain under evaluation.
  • FDA submission is not approval; this page does not treat CagriSema as an approved U.S. product.
Doctide’s verdict

The Satiety Duet has an actual trial program behind its score. Give that evidence its due, while keeping a studied combination, an improvised mixture and a regulatory decision on separate pages.

Questions readers ask

Plain-language answers

What is CagriSema?

CagriSema is a defined investigational combination of cagrilintide and semaglutide developed by Novo Nordisk.

Is CagriSema FDA-approved?

This record does not identify a final FDA approval. A regulatory submission is not approval.

Has the combination been studied in people?

Yes. REDEFINE 1 was a randomized, double-blind phase 3 trial; final labeling and longer-term questions remain unresolved.

Continue with the Peptide Guides for broader comparisons.

Editorial recordProfile editorial revision: October 4, 2026Prepared under the Church of Peptides evidence standardEditorial review: Church of PeptidesIndependent clinical review: none to dateContent evidence reviewed: September 14, 2026
Evidence ledger

Sources

  1. PubMed · REDEFINE 1, New England Journal of Medicine, 2025
  2. ClinicalTrials.gov · REDEFINE 1, NCT05567796
  3. Novo Nordisk · February 2, 2026 development update
  4. FDA · Drugs@FDA database

Conflict disclosure: REDEFINE 1 and the regulatory submission were sponsored by Novo Nordisk, the developer of CagriSema.

Fiction disclosure: Only the bold laboratory legend is invented. Marketing nicknames are identified as such; scientific and regulatory statements are sourced summaries.

Educational entertainment only. Not medical advice, diagnosis, dosing guidance, or a recommendation to obtain or use a product.

The Book of Trials

Follow the research journey

Join Subject One for six short chapters, following documented research questions and today’s evidence.

Read the CagriSema journey →